1 brand tagged as Insulin Glargine. Discover which parent companies own these brands.
Owned by Sanofi
Sanofi's long-acting insulin glargine for type 1 and type 2 diabetes, FDA approved April 2000, that reached peak global sales of $6.4 billion in 2015 before biosimilar competition from Basaglar, Semglee, and Rezvoglar significantly eroded its market share and revenues.
